Sign in

    Quest Diagnostics Inc (DGX)

    Q4 2023 Earnings Summary

    Reported on Jan 10, 2025 (Before Market Open)
    Pre-Earnings Price$128.43Last close (Jan 31, 2024)
    Post-Earnings Price$124.05Open (Feb 1, 2024)
    Price Change
    $-4.38(-3.41%)

    What went well

    • Quest Diagnostics expects operating margin expansion in 2024 driven by volume growth and cost reductions.
    • The company remains confident in achieving its long-term financial outlook of mid-single-digit revenue growth and high single-digit earnings growth beyond 2024, despite temporary headwinds in 2024.
    • Strong growth is anticipated in advanced diagnostics, particularly in Alzheimer's testing and the upcoming launch of the Haystack minimal residual disease (MRD) test, contributing to future revenue growth.

    What went wrong

    • Quest Diagnostics anticipates a decline in COVID-19 testing revenues of at least $175 million in 2024, which will serve as a revenue and earnings headwind.
    • The acquisition of Haystack Oncology is expected to be dilutive to adjusted EPS by approximately $0.20 in 2024, negatively impacting profitability. , ,
    • Increased interest expenses due to higher borrowings are expected to impact earnings by about $0.25 per share in 2024, as net interest expense is expected to increase to approximately $190 million. ,

    Q&A Summary

    1. Margin Expansion in 2024
      Q: Will operating margins expand in 2024 versus 2023?
      A: Management expects operating margins to expand in 2024, driven by volume growth and ongoing cost reductions, despite headwinds like COVID revenue decline and full-year Haystack dilution. They are confident about continued margin growth.

    2. Impact of PAMA Delay
      Q: How does the PAMA delay affect margins and investments?
      A: The PAMA delay removes a potential negative, allowing Quest to avoid difficult cuts and proceed with investments in areas like Alzheimer's testing, PFAS testing, and lab system upgrades.

    3. Haystack Progress and Dilution
      Q: What's the status of Haystack and its financial impact?
      A: Haystack is progressing as expected, with no incremental investment beyond initial guidance. The test will launch commercially in the first half of the year, with a full-year dilution of $0.15 to $0.20 in 2024.

    4. Share Repurchase Plans
      Q: What are the plans for share repurchases in 2024?
      A: Quest plans to offset equity dilution with share repurchases of approximately $250 million to $275 million, similar to the amount in Q4 2023.

    5. Volume Growth and Utilization
      Q: What are volume growth and utilization expectations for 2024?
      A: Volume growth is expected to continue slightly above normal market rates, supported by higher utilization observed in Q4 2023 and early 2024, despite some weather-related impacts in January.

    6. Price Stability with Health Plans
      Q: What are price expectations with health plans for 2024?
      A: Prices are expected to remain flat to slightly up in 2024, following successful renegotiations in 2023. Price per test provided a slight lift in 2023, and similar trends are anticipated.

    7. M&A Contribution to Growth
      Q: How much will M&A contribute to 2024 revenue growth?
      A: Acquisitions will contribute approximately 50 basis points to revenue growth in 2024, reflecting carryover from deals made in 2023, such as NewYork-Presbyterian and Lenco.

    8. Hospital Reference Testing Impact
      Q: How does increased hospital reference testing affect margins?
      A: Higher hospital reference testing, which carries higher gross margins and lower phlebotomy costs, positively impacted margins as this business grew faster than the overall portfolio in Q4 and the full year.

    9. Long-Term Earnings Growth Outlook
      Q: How confident are you in long-term earnings growth beyond 2024?
      A: Management remains confident in their long-term growth targets of mid-single-digit revenue growth and high-single-digit EPS growth, viewing 2024 headwinds as temporary and maintaining a strong acquisition pipeline.

    10. LDT Legislation and Haystack IP
      Q: How will LDT legislation affect you, and is Haystack at IP risk?
      A: Approximately 10% of Quest's tests are LDTs; they are prepared to comply with potential regulations. There is no IP risk with Haystack, as they are confident in their rights from Johns Hopkins.

    11. Investments in Alzheimer's Testing
      Q: What's the opportunity in Alzheimer's testing?
      A: Quest is expanding its blood-based Alzheimer's tests, experiencing double-digit growth in this area, and expects continued strong demand due to new therapeutic developments increasing awareness.

    12. AI Investments and Impact
      Q: How are AI investments expected to affect margins?
      A: Quest is investing in AI to optimize lab workflows, reduce labor, and improve efficiencies in areas like microbiology and pathology, which should yield margin benefits in the future.

    Related Publications